Jianzhong Lu - Publications

ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer.

Journal: Cellular signalling

Published: February 26, 2026

Targeting the FTO-ACSL4 Pathway: A Novel Mechanism for Sanguinarine Chloride-Induced Ferroptosis in Endometrial Cancer.

Journal: Biomedicines

Published: February 04, 2026

Angiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation.

Journal: Cancers

Published: January 23, 2026

Sanguinarine chloride exerts its antitumor effects on enzalutamide-resistant prostate cancer by inhibiting cell proliferation and promoting senescence via targeting AR signaling.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 21, 2025

Corrigendum to "Downregulation of S100A11 promotes T cell infiltration by regulating cancer-associated fibroblasts in prostate cancer" [Int. Immunopharmacol. 128 (2024) 111323].

Journal: International immunopharmacology

Published: August 29, 2025

Cytotoxic effect of bladder cancer oncolytic virus on bladder cancer stem-like cells via pyroptosis pathway.

Journal: Technology and health care : official journal of the European Society for Engineering and Medicine

Published: June 11, 2025

TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.

Journal: Molecular cancer therapeutics

Published: May 07, 2025

TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer.

Journal: Molecular cancer therapeutics

Published: May 07, 2025

Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer.

Journal: International immunopharmacology

Published: March 27, 2025

Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4.

Journal: Chinese medicine

Published: March 22, 2025

Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo.

Journal: FEBS open bio

Published: March 10, 2025

TAK-901, a novel EPHA2 inhibitor as a therapeutic strategy against prostate cancer.

Journal: Cellular signalling

Published: December 26, 2024